Pharmaceuticals, Biotechnology and Life Sciences
Swedish Orphan Biovitrum (Sobi) has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ.
e-Therapeutics’s Executive Director & Company Secretary Sean Nicolson is leaving the company in order to focus on other business commitments.
Active Biotech has reported net loss of € 1,6 million for Q4, which is decrease of loss comparing to the same period 2015 when the net loss was € 4,3 million.
Weifa ASA, Norwegian health company has reported net income of € 0,9 million for Q4 2016 which is increase comparing to the same period last year when the comapany had € 0,3 million loss. The company has more than tripled its net income for year 2016. It has reported € 2,03 million for whole 2016 and net income for the 2015 was € 0,65 million.
Vectura Group has reached a royalty cap on net sales of £9 million from selling GSK’s respiratory Ellipta products in 2016.
Adocia plans to license its diabetes treatment products, especially its most advanced program BioChaperone Lispro. The company’s boss said that cash position of €58 million will enable the company to push BioChaperone Lispro into phase 3 clinical trial.
“The rapid roll-out of our nationwide ambulatory clinic model, and our significant new participation in the Georgian pharmaceuticals market will continue to create further business development and cost efficiency opportunities over the next few years,” said the group’s CEO Nikoloz Gamkrelidze.
Navamedic, Norwegian medtech and pharmaceutical products company, has reported Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of €0,6 million which represents small increase comparing to same period last year when company’s EBITDA was slightly under zero.
Pharmapack Europe – organised by UBM EMEA – closed its 2017 edition, marking 20 years of its presence, as a major European event for pharmaceutical packaging and drug delivery devices. The top trends that emerged from the two-day event included: patient centricity, traceability, innovation, compliance and adherence.
As a part of Clintec’s – a privately-owned full-service Clinical Research Organisation (CRO) – 20th anninversary and reaching certain milestones after another year of growth, Clintec on Wednesday launched its new brand identity reflected in their newly created website.